Last reviewed · How we verify
VSA003
VSA003 is an investigational therapeutic targeting viral or cellular mechanisms relevant to its indication in phase 3 development.
At a glance
| Generic name | VSA003 |
|---|---|
| Also known as | AROANG3, Zodasiran |
| Sponsor | Visirna Therapeutics HK Limited |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available on VSA003's precise mechanism of action. As a phase 3 candidate from Visirna Therapeutics, it likely represents a novel therapeutic approach, but specific molecular targets and mechanistic details have not been widely disclosed in accessible literature.
Approved indications
Common side effects
Key clinical trials
- A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers (PHASE1)
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |